Wilson, E C F <br/><br/>
The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Jul 2007 
 - 1096-101 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1462-0324 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/kem054  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acute Disease<br/>Computer Simulation<br/>Cost-Benefit Analysis<br/>Cyclophosphamide--administration & dosage<br/>Day Care, Medical--economics<br/>Drug Costs<br/>Humans<br/>Immunosuppressive Agents--economics<br/>Infusions, Intravenous<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Lupus Nephritis--drug therapy<br/>Models, Economic<br/>Mycophenolic Acid--analogs & derivatives<br/>Prednisolone--economics<br/>Quality-Adjusted Life Years<br/>State Medicine--economics